Site icon Trend Bulletin

FDA Approves Selarsdi as a Biosimilar Treatment for Psoriasis and Psoriatic Arthritis

FDA Approves Selarsdi as a Biosimilar Treatment for Psoriasis and Psoriatic Arthritis

FDA Approves Selarsdi as a Treatment Option for Psoriasis and Psoriatic Arthritis

What is Selarsdi?

Selarsdi, manufactured by Alvotech and marketed by Teva, is a biosimilar to Stelara, a medication used to treat psoriasis and psoriatic arthritis. Biosimilars are highly similar to existing medications, but they are developed and manufactured by different companies.

Indications for Selarsdi Treatment

Selarsdi is indicated for the treatment of:

How Does Selarsdi Work?

Similar to Stelara, Selarsdi contains an active ingredient called ustekinumab, which targets the interleukin-12 (IL-12) and interleukin-23 (IL-23) proteins. These proteins play a role in the inflammatory response that leads to psoriasis and psoriatic arthritis. By blocking IL-12 and IL-23, Selarsdi can help reduce inflammation and improve symptoms.

Important Considerations

Search Query:
What are the conditions treated by Selarsdi, a biosimilar to Stelara?

also read:What Triggers Psoriatic Arthritis Development in Patients with Psoriasis?

Exit mobile version